Four 20 Pharma and Northern Green Canada have completed their first successful shipment of non-irradiated medical cannabis flower. This shipment from Toronto, Canada to Paderborn, Germany is the part of a larger supply agreement between Four 20 and NGC that will extend into 2021.
The shipped cannabis flower has been stringently tested, first in Canada for NGC by Eurofins, and subsequently, Four 20 commissioned an independent German laboratory to confirm the purity, THC content and quality of the flower. NGC and Four 20 set the highest standards in order to guarantee the patient receives the greatest possible degree of safety and effectiveness.
Lisa McCormack, President and CEO of NGC, commented: "This successful shipment represents a major milestone for our company. Following our recent EU GMP certification, our expansion into Germany will support patients who are facing an inconsistent availability of medical cannabis due to the current short supply. We are excited to work alongside Four 20 Pharma to provide quality medicine to the community."
"We take our promise of quality very seriously and we have been successful in delivering quality. We are certain that our first cannabis brand "420 NATURAL", free from any irradiation, will establish itself very quickly on the German market," explains Thomas Schatton, CEO of Four 20. "With a THC content range of 20 to 25%, the Indica dominant variety GG4 represents the basis of our future range of products. We look forward to continuing to ensure patient care with this first-class product. Long-term supply contracts, with high import quantities, will guarantee a constant supply. "
Germany is the largest medical cannabis market in Europe. It is poised to maintain and grow this presence in the years to come. NGC, together with Four 20 Pharma, is proud to be a part of the growth of this vital and dynamic market.